VC fund profile · evidence-aware directory data
Formation Bio Drug Development Accelerator Fund stages, portfolio and investment profile
Formation Bio announced $600M in commitments to its debut drug-asset fund in October 2026. It aims to acquire or license 10–15 Phase 1/2 programs over 3–5 years, with each asset housed in a NewCo. Formation Bio acts as GP through a subsidiary. Individual LPs, fees and final-close status were not disclosed. This is fund capital, not corporate equity.
Keep track of Formation Bio Drug Development Accelerator Fund
Save this profile to your VCT watchlist for a quick return.
Stage-based planning range
$100K–$1M
This is a planning range inferred from stage coverage, not a firm-disclosed check size.
Methodology: Stage bucket inferred from the rounds a fund leads or invests in.
No firm-specific check-size disclosure is recorded.
Investment stages
Leads: Not recorded
Participates: Not recorded
Sector focus
Not recorded
Geography
Not recorded
Founded Not recorded
Fund size / AUM
Not recorded
A separate fund-size evidence record is not yet available.
Portfolio in our directory
None yet
Linked startup profiles
Recent tracked investment
Not recorded
No dated round explicitly links this fund.
Rounds they lead
Rounds they invest
Last verified: Not recorded. Check-size evidence is labeled by basis so planning estimates are not presented as firm disclosures.
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.